Medication | Probiotic group (n = 34) | Placebo group (n = 36) | P |
---|---|---|---|
NSAID, n (%) | 7 (20.6) | 12 (33.3) | 0.239a |
median days (IQR) | 3.0 (1.0–7.0) | 4.5 (3.0–6.5) | 0.482b |
Antitussives, n (%) | 15 (44.1) | 19 (52.8) | 0.474 |
median days (IQR) | 5.0 (4.0–7.0) | 7.0 (5.0–8.0) | 0.241 |
Nasal decongestants, n (%) | 5 (14.7) | 3 (8.3) | 0.408 |
median days (IQR) | 5.0 (4.0–5.0) | 5.0 (4.0–5.0) | 0.785 |
Throat antiseptics, n (%) | 7 (20.6) | 11 (30.6) | 0.347 |
median days (IQR) | 5.0 (4.0–5.0) | 6.0 (5.0–8.0) | 0.044 |
Antispasmodics, n (%) | 0 (0.0) | 6 (16.7) | 0.018 |
median days (IQR) | - | 4.0 (2.0–5.0) | NAc |
Antidiarrheal, n (%) | 1 (2.9) | 1 (2.8) | 0.968 |
median days (IQR) | 1.0 (-) | 1.0 (-) | NA |
Antiplatelet, n (%) | 1 (2.9) | 1 (2.8) | 0.968 |
median days (IQR) | 11.0 (-) | 4 (-) | NA |
Herbs, n (%) | 1 (2.9) | 2 (5.6) | 0.593 |
median days (IQR) | 1.0 (-) | 14.0 (6.0–22.0) | NA |